Site Loader

ANVISA Resolution – RDC n. 17, of April 16th I – Internal code name as a reference and DCB, if any; DCB), with the amount used of each one, using the. ANVISA. BRAZILIAN HEALTH REGULATORY AGENCY. Brazilian . List of Brazilian Non proprietary Names (DCB). documento emitido pela Anvisa atestando que determinado esta- belecimento IX – Denominação Comum Brasileira (DCB) – nomenclatura.

Author: Dogami Kigashicage
Country: Brunei Darussalam
Language: English (Spanish)
Genre: Medical
Published (Last): 9 May 2008
Pages: 208
PDF File Size: 18.81 Mb
ePub File Size: 10.75 Mb
ISBN: 312-4-15714-164-4
Downloads: 66613
Price: Free* [*Free Regsitration Required]
Uploader: JoJozilkree

However, integral and universal access to therapeutic assistance does not mean access to all kinds of treatments.

This law is regulated by Decree No. What defences are available to product liability claims?

Suspend their distribution, commercialisation, and use. Brazilian Bar Association, Recent case law In Brazil, case law is not binding. Who is potentially liable for defective medicinal products?

Infor the first time the price readjustment index was above inflation, reaching a maximum of Anyone who commits these actions with products that:. Restrictions on foreign applicants Foreign manufacturers can market medicinal products in Brazil as imported goods, through local subsidiaries or local commercial representatives.

How are the prices of medicinal products regulated? Advertisements, visits by representatives, distribution of free drug samples or other gifts and sponsoring of meetings and seminars are all permitted, provided that these interactions do not influence a medical practitioners’ prescription decisions inappropriately.

Ministério da Saúde

For similar biological products, the following two regulatory pathways were introduced:. Anyone who imports, sells, displays for sale, stores for sale or, in any way, distributes or delivers for consumption a falsified, corrupted, adulterated or altered product.

Analysing patent applications related to pharmaceutical products and processes, jointly with the Brazilian Patent and Trademark Office BPTO Instituto Nacional da Propriedade Industrial prior consent analysisaccording to the updated proceedings set out in Resolution No. The name of the manufacturer and place where the medicine is manufactured country, state and city, in the case of imported products. The local subsidiaries or local commercial representatives must obtain an operating authorisation and licence, as well as marketing authorisation for each imported product.

  ITTEN A SZNEK MVSZETE PDF

Outline the key regulators and their powers in relation to medicinal product liability. Suggesting or encouraging diagnosis by the general public. The price charged by the company in foreign countries. The distribution is made by the federal, state and county public hospitals.

That prescription medicines will only be released on presentation of a receipt, and the means by which it can be presented to the establishment fax, e-mail or otherwise. Name and registration number in the Pharmaceutical Council of the pharmacist in attendance. Rationale, aims and methods to be used in the trial.

RESOLUÇÃO-RDC Nº 44, DE 26 DE OUTUBRO DE 2010

This is the main statute related to pharmaceutical products in Brazil. Advertising prescription medicines over the internet is prohibited, unless the advertisement is only accessible by professionals who can prescribe or dispense medicines see Question 16, Internet advertising. Two other pieces of legislation are also relevant:. Monitoring compliance and imposing penalties ANVISA, as well as the state and municipal bodies, are responsible for monitoring and enforcing compliance with food and drug laws.

What remedies are available to the claimant?

Medicinal product regulation and product liability in Brazil: overview | Practical Law

The cost per patient of treatment with the product. All the information that does not fit in the external packaging must be contained in the insert packaging. In the case of imported medicines and active pharmaceutical ingredients, in addition to the usual registration requirements, the company must also prove that the product is already registered in the country of origin Article 18, Law No. This enshrines the government’s duty to regulate the provision of health services and products, whether directly or through third parties, and provides for the Brazilian regulatory framework for pharmaceutical products, medical devices and pharmaceutical active ingredients.

  GUIAS JAPONESAS PANCREATITIS 2010 PDF

Publish the authorisation and licence in the Official Gazette. Any post-approval changes involving alterations, inclusions or cancellations must follow the procedures specified in Resolution No. It provides for, anvia other things, the production, commercialisation, advertising, anviza, inspection, quality control, penalties, importation and marketing approvals of medicines, drugs, pharmaceutical active ingredients, medical devices, cosmetics, household products and other products.

Biological products that require special care for maintenance and transport.

A specific provision allows for the postponement of those deadlines once, for one third of the statutory limit, under strict conditions. Generic medicines Resolution No.

Employing words that encourage consumption of the medicine, for example, “have”, “take”, “use “, “try”, and so on. Its contents are dvb updated. Restrictions Under Law No. Key stages and timing The key steps to obtain marketing approval are:. Internet advertising Advertising prescription medicines over the internet is prohibited, unless the advertisement is only accessible by professionals who are authorised to prescribe or dispense medicines Resolution No.